HB-EGF ASO

HB-EGF ASO is an antisense oligonucleotide designed to specifically target and downregulate heparin-binding EGF-like growth factor (HB-EGF) mRNA, thereby reducing HB-EGF protein expression. HB-EGF is a member of the epidermal growth factor (EGF) family and plays a role in lipid metabolism, vascular remodeling, and inflammation. In preclinical models, HB-EGF ASO administration results in suppressed hepatic VLDL production, reduced circulating triglyceride and cholesterol levels, improved insulin sensitivity, and protection against atherosclerosis and aortic aneurysm development. The mechanism of action involves gene silencing at the mRNA level, leading to decreased HB-EGF expression and downstream effects on lipid metabolic pathways and vascular inflammation. The drug has been studied almost exclusively in research settings and does not have clinical approval. The developer and manufacturer information is not specifically cited in the literature; published studies acknowledge grant funding from academic and government sources.[1][3][4][6]

Other names

heparin-binding EGF-like growth factor antisense oligonucleotideHB-EGF antisense oligonucleotide